In a recent update of an ongoing five year clinical trial conducted by the Chicago Blood Cancer Institute, patients with relapsing-remitting multiple sclerosis have experienced suppression of disease-related inflammation as a result of hematopoietic stem cell transplantations. The stem cells have the ability to regulate the autoimmune attack on the central nervous system, and have provided 82.8% of the patients with two years thus far of event-free disease remission.
While the patients are only three years into the five year phase II trial, the initial success of the treatment suggests a prolonged effectiveness of the stem cell treatment. Whereas most current therapies are plagued by disease breakthroughs and patient relapses, stem cell transplantations may provide patients with a long term therapeutic option that succeeds where conventional immunotherapy fails.
The Chicago Blood Cancer Institute’s research is an example of how scientists are gaining insights that will facilitate more effective stem cell treatments leading to better outcomes. To learn more about the value of preserving your own mesenchymal stem cells for use in future therapies and how to bank your own stem cells through a non-evasive and affordable method by recovering your dental pulp stem cells, visit StemSave or call 877-783-6728 (877-StemSave) today.
To view the full article, click here.
The Future of Regenerative Medicine is Now™.